The global HIV diagnosis market size is projected to reach $9.55 billion by 2030, advancing at a CAGR of 9/7% during 2021–2030. This will prominently be on account of the rising prevalence of AIDS and growing number of blood donations and blood transfusions, which are often conducted by tainted needles, especially in the poorly developed countries. In addition, the advantages of point-of-care instruments and rising healthcare expenditure are expected to aid the domain growth during the forecast period.
An HIV diagnosis involves a range of tests to detect the presence of human immunodeficiency virus. The infection attacks the immune system by targeting CD4 cells, also known as T cells, which help the immune system fight infections. HIV weakens the immune system of an infected individual, by reducing the number of T-cells, thus leading to AIDS. As per a government organization, around 40 million people were suffering from the virus in 2021.
The USFDA has recently approved a few home-based HIV analytical kits that can provide a result in 20 to 40 minutes, without the need to send the test sample to a laboratory. Home-based diagnosis devices are more convenient to use and less expensive, and they save time, thus making them increasingly popular in countries such as the U.S. and the U.K. The availability of home-based tests is expected to help more infected people than present becoming aware of their infection status, thereby allowing the players to tap into the untapped potential of the market.
Based on product, consumables are expected to witness the highest CAGR, of more than 11%, in the forecast period. Consumables include assays, kits, and reagents; the kits are available as complete and convenient packed test systems with a standard operating procedure. A patient has to follow the instructions to get the desired results. Kits offer rapid, easy-to-use, sensitive, and reliable detection of the infection, which is burgeoning the category demand.
The APAC HIV diagnosis market is expected to witness the highest CAGR, of more than 10%, in the forecast period. Because of the high prevalence of AIDS in the region, national, state, and provincial governments are taking steps to raise public awareness about the infection. As a result, the use of diagnostic instruments and test kits is increasing. The low literacy rates, as well as ignorance about HIV transmission modes, changing lifestyles, and unsafe sex are some of the factors contributing to an increase in the number of HIV cases. To reduce the risk of complications from the disease and increase the life expectancy of infected patients, government organizations in the region are focusing on improving HIV diagnostics and making the tests more accessible to the general public.
The major players operating in the HIV diagnosis market are Siemens AG, F. Hoffman-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories, and Hologic Inc.